1. JS1.1 Specific genetic alterations of breast tumors lead to Yo paraneoplastic cerebellar syndromes. (6th September 2019) Authors: Desestret, V; Pissaloux, D; Treilleux, I; Small, M; Robert, M; Rogemond, V; Picard, G; Psimaras, D; Alentorn, A; Honnorat, J Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. JS1.2 Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era. (6th September 2019) Authors: Vogrig, A; Fouret, M; Joubert, B; Picard, G; Rogemond, V; Pinto, A; Muñiz Castrillo, S; Roger, M; Raimbourg, J; Dayen, C; Grignou, L; Pallix-Guyot, M; Lannoy, J; Ducray, F; Desestret, V; Psimaras, D; Honnorat, J Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Issue 4 (17th October 2008) Authors: Honnorat, J; Cartalat-Carel, S; Ricard, D; Camdessanche, J Ph; Carpentier, A F; Rogemond, V; Chapuis, F; Aguera, M; Decullier, E; Duchemin, A M; Graus, F; Antoine, J C Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 80:Issue 4(2009) Page Start: 412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗